UWCCC uses the CCSG Protocol Specific Research (PSR) support for member's pilot clinical and/or translational research studies that would benefit from timely funding. CCSG PSR funding supports the translation of UWCCC research originating from novel laboratory or clinical observations into clinical testing. UWCCC Scientific Programs support the translation and facilitation of these research ideas into the clinic. In addition to benefiting UWCCC through investigator-initiated research efforts for the local community of cancer patients, this funding mechanism also benefits our Wisconsin Oncology Network (WON) by allowing more rapid dissemination of novel cancer therapies throughout the state of Wisconsin. UWCCC Scientific Programs conducting clinical research such as Experimental Therapeutics or Imaging and Radiation Sciences provide structure for clinical research. This has resulted in disease groups having research nurse and data management staff adequate for the conduct of ongoing trials. However the extent of resources available to each group does vary. Therefore, UWCCC provides additional support for short term, feasibility and Phase I clinical trials originating from scientific investigators within UWCCC. Through UWCCC Data and Safety Monitoring System, oversight, auditing and monitoring for all clinical trials is accomplished. In addition, the OnCore database supports these clinical trials assuring data are accurately, timely and completely captured in the database. Criteria for support of these clinical trials are as follows: ? Trial should be high priority, innovative, feasibility (pre Phase I, pilot) and Phase I institutional clinical interventions focusing on initial early phase testing of a candidate agent or device for diagnosis, prevention, detection, or treatment of cancer. Support is not meant for all early phase I trials, for later phase trials, or for studies that do not involve testing of an agent or device. ? Trials must be conceptualize/designed by UWCCC members. ? Trials must be of short duration (likely one year or less.) ? Trials receiving support from other peer reviewed research grants, cooperative agreements, and contracts are ineligible. Trials may receive partial support from industry assuming all other criteria are met. ? Trials must be approved by UWCCC's PRMS. ? Funding is restricted to research nurses and data managers directly involved trial conduct.

Public Health Relevance

The PSR funds allocated each year are applied to investigator-initiated short term, feasibility and Phase I clinical trials to support the efforts of research nurses and data managers for these projects. The PSR mechanism provides critical support for the growing volume and diversity of scientifically novel investigator initiated clinical research at UWCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762777
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$101,057
Indirect Cost
$59,442
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:
Fu, Anqi; Oberholtzer, Sydney M; Bagheri-Fam, Stefan et al. (2018) Dynamic expression patterns of Irx3 and Irx5 during germline nest breakdown and primordial follicle formation promote follicle survival in mouse ovaries. PLoS Genet 14:e1007488
Ni, Dalong; Jiang, Dawei; Kutyreff, Christopher J et al. (2018) Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 9:5421
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Farrell, Emily; Armstrong, Annie E; Grimes, Adrian C et al. (2018) Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling. Front Physiol 9:1442
Net, Jose M; Whitman, Gary J; Morris, Elizabteh et al. (2018) Relationships Between Human-Extracted MRI Tumor Phenotypes of Breast Cancer and Clinical Prognostic Indicators Including Receptor Status and Molecular Subtype. Curr Probl Diagn Radiol :
Jiang, Dawei; Ge, Zhilei; Im, Hyung-Jun et al. (2018) DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2:865-877
Seok, Seung-Hyeon; Ma, Zhi-Xiong; Feltenberger, John B et al. (2018) Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J Biol Chem 293:1994-2005
Chapelin, Fanny; Capitini, Christian M; Ahrens, Eric T (2018) Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. J Immunother Cancer 6:105
Ni, Dalong; Ferreira, Carolina A; Barnhart, Todd E et al. (2018) Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc 140:14971-14979

Showing the most recent 10 out of 1528 publications